Alaunos Therapeutics (TCRT) vs Virax Biolabs Group (VRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Virax Biolabs Group is the larger company by market cap ($2.5 million vs $2.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TCRT | VRAX |
|---|---|---|
| Share price | $0.7858 | $1.87 |
| Market cap | $2.30M | $2.52M |
| 1-day change | +0.61% | -6.03% |
| EPS (TTM) | $-1.76 | $-12.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.50 | $21.75 |
| 52-week low | $0.72 | $1.81 |
| Distance from 52-week high | -82.54% | -91.40% |
| Average volume | 797.20K | 650.11K |
| Shares outstanding | 2.93M | 1.34M |
| Employees | 1 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Alaunos Therapeutics
TCRT stock →Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
About Virax Biolabs Group
VRAX stock →Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 26 employees
TCRT vs VRAX FAQ
Which is bigger, Alaunos Therapeutics or Virax Biolabs Group?
Virax Biolabs Group (VRAX) is larger, with a market capitalization of $2.52M compared with $2.30M for Alaunos Therapeutics (TCRT).
Are Alaunos Therapeutics and Virax Biolabs Group in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Alaunos Therapeutics and Biotechnology: In Vitro & In Vivo Diagnostic Substances for Virax Biolabs Group.